Key Points
- Vericel insider Sean Flynn sold 15,000 shares on June 18 at an average price of $40.21, totaling about $603,150. After the sale, he held 1,647 shares, a 90.11% reduction in ownership.
- Vericel shares were trading slightly higher, opening at $40.47, near the stock’s 52-week high of $43.57. The company has a market cap of about $2.07 billion and a P/E ratio of 96.36.
- Recent results showed strong revenue growth: Vericel reported Q1 EPS of -$0.12, better than analyst expectations, and revenue of $68.43 million, up 30.1% year over year. Analysts currently have a consensus rating of Hold with a $52.50 price target.
Vericel Corporation (NASDAQ:VCEL - Get Free Report) insider Sean Flynn sold 15,000 shares of the company's stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $40.21, for a total value of $603,150.00. Following the transaction, the insider owned 1,647 shares of the company's stock, valued at approximately $66,225.87. This trade represents a 90.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Vericel Trading Up 0.9%
VCEL opened at $40.47 on Tuesday. The business has a 50 day moving average of $35.45 and a 200-day moving average of $35.64. The stock has a market capitalization of $2.07 billion, a price-to-earnings ratio of 96.36 and a beta of 1.12. Vericel Corporation has a 1-year low of $28.95 and a 1-year high of $43.57.
Vericel (NASDAQ:VCEL - Get Free Report) last announced its earnings results on Thursday, May 7th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.15) by $0.03. Vericel had a net margin of 7.35% and a return on equity of 6.41%. The business had revenue of $68.43 million for the quarter, compared to analyst estimates of $63.68 million. During the same quarter in the previous year, the firm posted ($0.23) earnings per share. Vericel's revenue was up 30.1% compared to the same quarter last year. Equities analysts predict that Vericel Corporation will post 0.49 EPS for the current year.
Wall Street Analysts Forecast Growth
VCEL has been the topic of several research reports. Weiss Ratings upgraded Vericel from a "sell (d)" rating to a "sell (d+)" rating in a research note on Tuesday, June 16th. Leerink Partners reissued an "outperform" rating and set a $46.00 price objective on shares of Vericel in a report on Tuesday, March 10th. Wall Street Zen lowered Vericel from a "buy" rating to a "hold" rating in a report on Sunday, June 14th. HC Wainwright restated a "buy" rating and set a $64.00 price objective on shares of Vericel in a research report on Friday, May 8th. Finally, Truist Financial cut their target price on Vericel from $48.00 to $42.00 and set a "buy" rating for the company in a research note on Wednesday, April 15th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $52.50.
View Our Latest Analysis on VCEL
Institutional Investors Weigh In On Vericel
Several large investors have recently modified their holdings of VCEL. Kestra Advisory Services LLC bought a new position in shares of Vericel during the 4th quarter worth approximately $27,000. Huntington National Bank grew its position in Vericel by 51.3% in the third quarter. Huntington National Bank now owns 805 shares of the biotechnology company's stock valued at $25,000 after acquiring an additional 273 shares during the period. Quarry LP acquired a new position in Vericel during the fourth quarter worth $31,000. Farther Finance Advisors LLC raised its stake in Vericel by 116.5% during the fourth quarter. Farther Finance Advisors LLC now owns 970 shares of the biotechnology company's stock worth $35,000 after acquiring an additional 522 shares in the last quarter. Finally, Truvestments Capital LLC lifted its holdings in shares of Vericel by 175.4% during the fourth quarter. Truvestments Capital LLC now owns 1,534 shares of the biotechnology company's stock valued at $55,000 after acquiring an additional 977 shares during the period.
About Vericel
(
Get Free Report)
Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company's expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.
Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
